Increased systemic IL-6 levels indicate inflammation as a determinant component in renal cell carcinoma development
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinical and Biomedical Research |
Texto Completo: | https://seer.ufrgs.br/index.php/hcpa/article/view/108350 |
Resumo: | Introduction: Renal cell carcinoma (RCC) is one of the most prevalent kidney tumors. It is believed that inflammation is a key factor for cancer progression and spread since inflammatory markers are generally associated with poor prognosis in RCC patients. Cytokines are cell communication molecules that act in both healthy and pathological situations. Of note, the processes of tumor growth and progression are mediated by cytokines. Recent findings suggest that cytokine level measurements could be used for cancer monitoring and prognosis.Methods: This study characterized and compared the systemic profile of different cytokines associated to the classical Th1, Th2 and Th17 immune responses in plasma samples from RCC patients (n=25) and healthy controls (n=29). Cytokine levels (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, and IL-17A) were evaluated by flow cytometry using BD Cytometric Bead Array (CBA) kit.Results: No statistical difference in systemic IL-2, IL-4, IL-10, IL-17A, TNF, and INF-γ levels were observed between RCC patients and controls (p>0.05). On the other hand, higher systemic IL-6 levels were observed in RCC patients in comparison to controls (p=0.0034).Conclusions: This study highlights the importance of assessing the impact of IL-6 on RCC pathogenesis and its potential role as a biomarker of disease progression. |
id |
UFRGS-20_b06119f07f2a6ab5e7d8dc921e991aa4 |
---|---|
oai_identifier_str |
oai:seer.ufrgs.br:article/108350 |
network_acronym_str |
UFRGS-20 |
network_name_str |
Clinical and Biomedical Research |
repository_id_str |
|
spelling |
Increased systemic IL-6 levels indicate inflammation as a determinant component in renal cell carcinoma developmentCBAcytokinesIL-6inflammationrenal cancerIntroduction: Renal cell carcinoma (RCC) is one of the most prevalent kidney tumors. It is believed that inflammation is a key factor for cancer progression and spread since inflammatory markers are generally associated with poor prognosis in RCC patients. Cytokines are cell communication molecules that act in both healthy and pathological situations. Of note, the processes of tumor growth and progression are mediated by cytokines. Recent findings suggest that cytokine level measurements could be used for cancer monitoring and prognosis.Methods: This study characterized and compared the systemic profile of different cytokines associated to the classical Th1, Th2 and Th17 immune responses in plasma samples from RCC patients (n=25) and healthy controls (n=29). Cytokine levels (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, and IL-17A) were evaluated by flow cytometry using BD Cytometric Bead Array (CBA) kit.Results: No statistical difference in systemic IL-2, IL-4, IL-10, IL-17A, TNF, and INF-γ levels were observed between RCC patients and controls (p>0.05). On the other hand, higher systemic IL-6 levels were observed in RCC patients in comparison to controls (p=0.0034).Conclusions: This study highlights the importance of assessing the impact of IL-6 on RCC pathogenesis and its potential role as a biomarker of disease progression.HCPA/FAMED/UFRGS2021-10-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed ArticleAvaliado por Paresapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/108350Clinical & Biomedical Research; Vol. 41 No. 3 (2021): Clinical and Biomedical ResearchClinical and Biomedical Research; v. 41 n. 3 (2021): Clinical and Biomedical Research2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSenghttps://seer.ufrgs.br/index.php/hcpa/article/view/108350/pdfCopyright (c) 2021 Clinical and Biomedical Researchinfo:eu-repo/semantics/openAccessCechim, GiovanaEllwanger, Joel Henriquede Lima Kaminski, ValériaBerger, MiltonBogo Chies, José Artur2024-01-19T14:13:25Zoai:seer.ufrgs.br:article/108350Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2024-01-19T14:13:25Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.none.fl_str_mv |
Increased systemic IL-6 levels indicate inflammation as a determinant component in renal cell carcinoma development |
title |
Increased systemic IL-6 levels indicate inflammation as a determinant component in renal cell carcinoma development |
spellingShingle |
Increased systemic IL-6 levels indicate inflammation as a determinant component in renal cell carcinoma development Cechim, Giovana CBA cytokines IL-6 inflammation renal cancer |
title_short |
Increased systemic IL-6 levels indicate inflammation as a determinant component in renal cell carcinoma development |
title_full |
Increased systemic IL-6 levels indicate inflammation as a determinant component in renal cell carcinoma development |
title_fullStr |
Increased systemic IL-6 levels indicate inflammation as a determinant component in renal cell carcinoma development |
title_full_unstemmed |
Increased systemic IL-6 levels indicate inflammation as a determinant component in renal cell carcinoma development |
title_sort |
Increased systemic IL-6 levels indicate inflammation as a determinant component in renal cell carcinoma development |
author |
Cechim, Giovana |
author_facet |
Cechim, Giovana Ellwanger, Joel Henrique de Lima Kaminski, Valéria Berger, Milton Bogo Chies, José Artur |
author_role |
author |
author2 |
Ellwanger, Joel Henrique de Lima Kaminski, Valéria Berger, Milton Bogo Chies, José Artur |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Cechim, Giovana Ellwanger, Joel Henrique de Lima Kaminski, Valéria Berger, Milton Bogo Chies, José Artur |
dc.subject.por.fl_str_mv |
CBA cytokines IL-6 inflammation renal cancer |
topic |
CBA cytokines IL-6 inflammation renal cancer |
description |
Introduction: Renal cell carcinoma (RCC) is one of the most prevalent kidney tumors. It is believed that inflammation is a key factor for cancer progression and spread since inflammatory markers are generally associated with poor prognosis in RCC patients. Cytokines are cell communication molecules that act in both healthy and pathological situations. Of note, the processes of tumor growth and progression are mediated by cytokines. Recent findings suggest that cytokine level measurements could be used for cancer monitoring and prognosis.Methods: This study characterized and compared the systemic profile of different cytokines associated to the classical Th1, Th2 and Th17 immune responses in plasma samples from RCC patients (n=25) and healthy controls (n=29). Cytokine levels (IL-2, IL-4, IL-6, IL-10, TNF-α, IFN-γ, and IL-17A) were evaluated by flow cytometry using BD Cytometric Bead Array (CBA) kit.Results: No statistical difference in systemic IL-2, IL-4, IL-10, IL-17A, TNF, and INF-γ levels were observed between RCC patients and controls (p>0.05). On the other hand, higher systemic IL-6 levels were observed in RCC patients in comparison to controls (p=0.0034).Conclusions: This study highlights the importance of assessing the impact of IL-6 on RCC pathogenesis and its potential role as a biomarker of disease progression. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-10-05 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Peer-reviewed Article Avaliado por Pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://seer.ufrgs.br/index.php/hcpa/article/view/108350 |
url |
https://seer.ufrgs.br/index.php/hcpa/article/view/108350 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://seer.ufrgs.br/index.php/hcpa/article/view/108350/pdf |
dc.rights.driver.fl_str_mv |
Copyright (c) 2021 Clinical and Biomedical Research info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2021 Clinical and Biomedical Research |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
HCPA/FAMED/UFRGS |
publisher.none.fl_str_mv |
HCPA/FAMED/UFRGS |
dc.source.none.fl_str_mv |
Clinical & Biomedical Research; Vol. 41 No. 3 (2021): Clinical and Biomedical Research Clinical and Biomedical Research; v. 41 n. 3 (2021): Clinical and Biomedical Research 2357-9730 reponame:Clinical and Biomedical Research instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Clinical and Biomedical Research |
collection |
Clinical and Biomedical Research |
repository.name.fl_str_mv |
Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
||cbr@hcpa.edu.br |
_version_ |
1799767056210460672 |